AbbVie Inc. (ABBV)
5 Things to Know Before the Stock Market Opens
Stocks are having a quiet morning Monday as investors come off a long holiday weekend with a close eye on peace talks between the U.S. and Iran; a second day of negotiations in Switzerland has reportedly concluded after renewed threats against Iran from President Trump and continued attacks in Lebanon by Israel made for an eventful first day of talks; earnings from FedEx and Micron are on tap this week, along with the release of the Fed's preferred measure of inflation; SpaceX shares are poised to start this week with a third straight day of declines; and shares of Apogee Therapeutics are soaring on news it is being acquired by AbbVie for $11 billion. Here's what you need to know today.
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
AbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash in a deal that bolsters the biopharmaceutical company's immunology and inflammation portfolio.
AbbVie would gain an experimental eczema drug by buying biotech: report
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
AbbVie: Immunology Cash Flow Funds Oncology Expansion
I continue to cover AbbVie with a 'Buy' rating due to its R&D achievements. So, in the past 3 months, Decnupaz and Skinvive by Juvederm have received FDA approvals. Moreover, a week ago, AbbVie reported promising results from the Phase 3 CLL14 trial for the treatment of chronic lymphocytic leukemia patients.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
In the most recent trading session, AbbVie (ABBV) closed at $216.49, indicating a -2.14% shift from the previous trading day.
3 Dividend Stocks That Pay You More Every Single Year
Income investors keep coming back to the same playbook in choppy markets: own businesses that have raised their payouts every single year, no matter what the economy is doing.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie: Maintaining My Strong Buy Rating After Label Expansion
AbbVie maintains strong momentum in immunology, with Skyrizi and Rinvoq offsetting Humira declines and driving double-digit revenue growth. I reaffirm a 'Strong Buy' rating, supported by expanding indications for Skyrizi in Crohn's Disease and Rinvoq in alopecia areata and vitiligo. Skyrizi's subcutaneous induction for Crohn's Disease, validated by phase 3 AFFIRM data, targets further market share and revenue acceleration.
This $15 Billion Operational Beat Just Rewrote the Entire Bear Thesis for AbbVie
For income investors weighing biopharma exposure, the dividend question on AbbVie (NYSE:ABBV | ABBV Price Prediction) just got a lot easier to answer.
AbbVie Stock Will Hit $300 on This Date
AbbVie (NYSE:ABBV | ABBV Price Prediction) has quietly become one of healthcare's most underrated growth stories.
Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
AbbVie (ABBV) Rises Higher Than Market: Key Facts
AbbVie (ABBV) closed at $227.73 in the latest trading session, marking a +1.32% move from the prior day.
